
Tracy King
428 posts

Tracy King
@MMKingT
Haem Nurse - MM focus - passionate about real world optimal drug access / outcomes for all


📌Abstract submissions are open for the 10th Nursing & Allied Health Symposium and the 23rd IMS Annual Meeting! Get started today: bit.ly/41qoY0E #IMS26

The #IMS26 preliminary program is now available! View the schedule for Glasgow and register today ➡️ bit.ly/4cdFJkH



How outcomes in relapsed/refractory multiple myeloma changed, from 1986 to 2026

4/ Thank you to all physicians around world who completed survey and to @BrJHaem reviewers! Special thanks to my partner-in-crime @GKaurMD on this, @VincentRK for encouraging us to push this to finish line, and our 🇦🇺🇮🇳🇨🇦🇺🇸 co-authors! Link to article: onlinelibrary.wiley.com/doi/10.1111/bj…

It has been great to visit beautiful Australia. Thank you Professor Joy Ho for welcoming me to Royal Prince Alfred and for showing me around beautiful Sydney! The myeloma community is close knit and colleagues are dear friends.

Primary IVIG PPx with BCMA bsAbs in myeloma #MMsm: now in more guidelines! New CLML expert recs by @paurotero et al. Many nice pearls about SUD & dosing. Also this 👇🏼 Withholding IVIG based on IgG < 400 mg/dL (4 g/L) is playing with fire, so - if needed - use higher threshold.

Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis: corticosteroid-sparing regimens warrant prospective investigation across the gamut of plasma cell disorders @RahulBanerjeeMD @vsanchorawala @jmikhaelmd ascopubs.org/doi/10.1200/JC…

@OncBrothers @BijoyTelivala Agreed with both of you! IFM 2017-03 is leading the way here - with SC dara in any line including SMM, I ditch all pre-meds after 2 cycles including dex. @jmikhaelmd @Bethfaiman @MMKingT and I actually have a JCO paper about #downwithdex coming out next week - more soon!







Our thoughts are with the injured, their families and those who have lost loved ones because of this tragedy. On Sunday we issued several life-threatening orders for O- blood, in the wake of the incident at Bondi. Please make an appointment if you can. app.lifeblood.com.au/XW3k/d9wncrn5



TecLille: Tec+Dara in transplant ineligible NDMM n=37; median age 73 (!) Very high MRD negativity rates even at 6 months! Very interesting correlatives, including clonotypic peptide sequencing and sBCMA. No progressions. No deaths. 14% grade 3+ infections (nearly everyone got IVIg starting within first cycle). If this regimen can be so well tolerated upfront even in older adults, that bodes very well for the future of bispecific antibodies in frontline therapy.







